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Scientific Note
AbstractMost data supporting the widely accepted relative biological effectiveness (RBE)value of 1.1 for therapeutic proton beams are from radiobiological experimentswith relatively high doses per fraction. The purpose of this study was to estimatebias in RBE that differences in dose levels between these experiments and protonradiotherapy treatments may cause. The linear quadratic model was applied tocalculate, using prior experimental data, RBE variations with dose and / ratio fordoses delivered in a standard fractionation regimen. The results suggest that theRBE measured at relatively high doses per fraction typical for a radiobiologicalexperiment underestimates the RBE of proton radiotherapy with a standardfractionation. The bias increases with decreasing radiation dose and decreasing
/ ratio, suggesting that, if differences in dose levels are not accounted for, theremay be a large underestimation of biological effects in late-responding tissuesexposed to low doses of radiation.
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1. IntroductionIn proton radiotherapy, a generic proton relativebiological effectiveness (RBE) value of 1.1 is widelyaccepted.1 However, several studies investigating thebiological effects of proton and photon beams at themolecular and cellular levels have reported largedifferences between the two types of radiation.2-4 Theseresults reflect important differences in the patterns ofmolecular damage induced by protons and photons andin the mechanisms by which that damage is repaired.They also suggest that, for some biological endpoints,the proton RBE value can be significantly greater thanone.An RBE value of 1.1 is consistent with the average RBEvalue calculated in a comprehensive review of pertinentin vivo studies.5 Those calculations, however, wereaffected by the limitations of the radiobiological dataavailable at that time. For example, the experimentalRBE data used in those calculations were dominated byonly four biological endpoints, all from murine studies:survival after thoracic irradiation, inactivation ofintestinal crypt cells, acute skin reactions, andinactivation of fibrosarcoma cells. In addition, the datawere heavily biased toward early-responding,
high-/-ratio tissues. Furthermore, most of the RBEmeasurements were made at locations within thespread-out Bragg peak. Therefore, the linear energytransfer (LET) spectra were similar to the LET spectra inthe target volume covering the tumor but different fromthe LET spectra in the normal tissues outside the targetvolume. Finally, the doses per fraction in thoseexperiments were typically much higher than thestandard fraction dose of approximately 2 Gy, exceeding10 Gy per fraction in most cases. Measurements takendirectly at doses of 2 Gy or less constitute only aboutone-tenth of the sample. Consequently, the use of theaverage RBE derived from these data is associated withless uncertainty in hypofractionated treatments than instandard fractionation treatments.In summary, a proton RBE of 1.1 is supported by limitedand skewed radiobiological data and is most appropriatefor assessment of tumor control (but not normal tissuecomplication probability) in hypofractionatedtreatments, excluding malignancies characterized byrelatively low / ratios, such as prostate cancer.6 Toderive more confident estimates of proton RBE outsidethe stated scope, additional radiobiological data are
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needed. These data should be collected under conditionsapproximating those of specific types of treatment interms of dose ranges, fractionation schemes, and tissuetypes.Published in vitro data provide some indication of themagnitude of possible bias in the estimated proton RBEvalue. Dose per fraction in RBE measurements in vitrotends to be lower than in measurements in vivo, as canbe seen from the data compiled by Paganetti et al.5 Also,this compilation included in vitro data with relativelylow / ratios. These observations may help explain thedifference in the reported average in vivo and in vitroRBE values in Paganetti et al.’s study (1.10 and 1.22,respectively). In addition, Gerweck and Kozin7demonstrated a particularly strong dose dependence ofRBE for V79 cells. In V79 cell line, the proton RBE valuewas 30% higher at the cell survival level thatcorresponded to a photon dose of approximately 2 Gythan at the level that corresponded to a photon dose of 6Gy. At approximately 2 Gy, the proton RBE level wasrather high (about 1.6).Paganetti et al. noted an increased RBE value at lowerdoses per fraction.5 An earlier in vivo study reportedmore specifically that "RBEs were found to increaseslightly (about 4%) with decreasing dose, in theinvestigated dose range (12-17 Gy)".8 However, inPaganetti et al.’s study the increase in RBEs wasapparently deemed negligible, at least for in vivosystems.5 The lack of a clear trend in that data set likelyreflects the fact that the data are mostly fromexperiments with early responding tissues, asmentioned earlier. Therefore, the trend toward higherRBE values, if any, would be expected to be weak. Withtypical experimental uncertainties of 5-10%, and whichare much higher in some cases, any trend would bedifficult to identify. On the other hand, the fractionationschedule in radiotherapy is known to have a profoundeffect on treatment outcomes. Furthermore, evenrelatively small RBE variations, which are difficult todetect and quantify in in vivo experiments, may have astatistically significant impact on a population ofradiotherapy patients. Given the limitations ofexperimental data, there is a clear need for a theoreticalanalysis. The linear quadratic model is an obvious choicefor such an undertaking, since it has been used in clinicalstudies for decades, in particular for the analysis anddesign of fractionation schedules.9In the present study, the linear quadratic model wasapplied to previously reported data on in vivo RBE5 toestimate RBE variations due to variations of radiationdose and tissue / ratios. To my knowledge, no suchanalysis has been previously reported, although it hasbeen previously indicated that the RBE may increasewith decreasing dose and/or decreasing / ratios.7 Thepresent study addresses this possible problemquantitatively using a general formalism. The purpose of
the study was to estimate the bias and uncertainties inproton RBE for the standard radiotherapy fractionationschedule when it is derived from radiobiologicalexperiments performed at doses per fraction higherthan those in the radiotherapy treatments, withoutcorrection for differences in fraction size. The study wasalso intended to assess the magnitude of potentialerrors, identify major trends, and provide preliminarydata that may aid in the design of future experiments.The approach, however, is prone to large uncertaintiesdue to the limitations of the available experimental data.Therefore, the results reported in this study cannot beapplied directly to alter current proton radiotherapypractices.
2. Methods and MaterialsThis section describes a simple method of calculating theRBE for clinically relevant dose fractionation schemesusing RBE data generated from arbitrary doses ordoses-per-fraction experiments. The method is based onthe linear quadratic model. Let d and dp be doses perfraction delivered to a point of interest within an organor tissue, where the subscripts  and p refer to photonand proton radiation fields, respectively. To adhere tothe conventions of proton therapy, the reference photonfield here is that produced by a 60Co source. This sourceis widely used in radiobiological experiments. Thenumbers of photon and proton dose fractions are n and
np, respectively. The parameters of the model are , ,
p, and p. The proton RBE is the ratio of the total photonand proton doses, D = n d and Dp = np dp, that causeequal biological effect. In the standard basic form of thelinear quadratic model, the equal effect condition isgiven by this equation9:
   22 ppppp ddnddn    .      (1)This equation does not include any time-dependentfactors to account for effects related to cell kinetics, suchas cell proliferation. Calculating the impact of cellkinetics on the RBE is outside the scope of this study.To reduce the number of parameters, two additionalassumptions are made. The first assumption is that thenumber of fractions is the same for both photon andproton irradiations, i.e., n = np. This condition is typicallymet in radiobiological experiments designed to measurethe proton RBE. The second assumption is thatparameter  does not depend on radiation quality, i.e., = p. This assumption is supported by the theory of dualradiation action that attributes the quadratic term to theintertrack interactions of radiation-inducedsublesions.10 A study by Coutrakon et al.11 provides agood example of experimental data on the dependenceof parameters  and  on radiation quality. Coutrakon et
al. measured cell survival curves at multiple depthswithin typical therapeutic proton beams at three
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different beam energies. The ratio p/ ranged from 1.0to 1.4 with a median of 1.2. In contrast, the ratio p/was much larger, with values ranging from 2.0 to 3.3 anda median of 2.5. For high LET radiation of approximately30-100 keV/m, experimental data show a dependenceof parameter  on LET.12 For protons of therapeuticenergies, experimental data on variations of  withradiation quality, or the lack thereof, are far lessconclusive, especially in vivo. It is therefore a sensibleapproach to follow theoretical arguments suggestingthat  = p.10 This assumption is also consistent with thetrend of the RBE approaching a value of one at highdoses, a tendency which, for example, is observed in fastneutrons.13 A more elaborate model for  would bedifficult to justify.






















,      (2)
Here R1 and R2 are RBEs measured at doses dp1 and dp2,and b =  dp2 /  is a dimensionless variable.Qualitatively, in this formalism the RBE increases withdecreasing dose because  is more affected by radiationquality than is . At sufficiently high doses, the RBEtends to 1, which, as we have mentioned, is consistentwith fast neutron data for several endpoints13 and is amathematical corollary of the assumption  = p.
Table 1: RBE dependence on photon dose per fraction: comparison of other researchers’ measurements14-16with presentcalculations.Reference Dose,Gy RBEmeasure-ments  / *Gy Dose,Gy RBE Dose,Gy RBEPriormeasurements Presentcalculations Priormeasurements PresentcalculationsBlomquist
et al.14
9.9 1.15 3.65 6.5 1.28  0.21 1.22 3.0 1.63  0.63 1.41Tang
et al.15 8.2 1.12 6.52 3.9 1.18  0.04 1.19 1.2 1.27  0.05 1.30Wouters
et al.16 10.0 1.19 5.00 3.8 1.28 1.37 1.9 1.49 1.54*  /  used in the calculations
Figure 1: Calculated proton RBE versus  / ratio for total proton doses of 5, 30, and 67.3 Gy delivered in 37 fractions.Black line, 67.3 Gy; blue line, 30 Gy; and red line, 5 Gy. The confidence intervals are shown for the dose of 30 Gy and  / =2, 5.5, and 9 Gy.
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3. Results and DiscussionTo test the described RBE calculation method, I useddata from in vitro studies that reported proton RBEs forcell survival at several survival levels.14-16 The lowestsurvival levels tested in those previous studies were atphoton doses per fraction of approximately 8-10 Gy. Weused the  / ratios and RBEs at the lowest survivallevels reported in those studies to calculate the RBE atlower doses. The analysis was limited to measurementsmade approximately in the middle of a spread-out Braggpeak. Wouters et al. fitted the cell survival data forphotons into a two-population, linear quadratic model.16The measured RBEs presented in Table 1 for that studywere derived from the two-population model because itmost closely fits the measured points. The  / rationeeded to apply my formalism was taken from aseparate fit in the high-dose region because the purposeof these calculations was to extend high-dose RBE datato the low-dose range. My calculated RBEs at low dosesare compared in Table 1 with the prior measurements atthe same doses.14-16 Agreement between ourcalculations and the published measurements ofBlomquist et al. and Tang et al.14,15 was withinexperimental uncertainties. Discrepancies between thepresent calculations and the data reported by Wouters
et al.16 may have exceeded experimental uncertainties(these were reported in a graph only). The differences,however, were within 10%. The discrepancies werecaused by deviations from our assumption that  = pand, in the case of the photon measurements reportedby Wouters et al.16, by deviations from the simple linearquadratic model.The agreement of my model with in vivo data wasinvestigated using a subset of the data compiled byPaganetti et al5, where RBEs were reported at doses of 2Gy or less. This subset is comprised of four studies: threefrom Harvard University17-19 and one, more recent, fromthe National Accelerator Center in South Africa.20 Two ofthe studies17,20 reported on the survival of jejunumintestinal crypt cells in mice. In both of these studies, thedose-effect dependences were fitted with the linearmodel, i.e.  =p = 0.  The reported RBE values rangedfrom 1.14 to 1.23, and the number of fractions rangedfrom 1 to 20. The RBE value in these studies did not varysignificantly with fractionation. This finding is consistentwith our model applied to the special case of  =p = 0.Furthermore, Gueulette et al concluded that the “clinicalRBE value of 1.10 appears low.”20An RBE value of 1.16 ± 0.12 (average ± standarddeviation) was reported at a cell survival level of 0.5 fora spontaneous murine tumor.18 The  / ratios werein the range of 8.0 - 43 Gy, with a median of 24 Gy. I used
 ,  , and RBEs at the survival level of 0.1 reported inUrano et al.’s study and applied my model to calculateRBE values at a survival level of 0.5. The calculatedaverage RBE, 1.22 ± 0.10, was higher than that reported
by Urano et al18, but not significantly. The maximumnumber of fractions studied (Urano et al 18) was 10. Inthat case the measured18 and calculated RBE valueswere 1.42 and 1.36, respectively. It should be noted thatthe data from these three studies concern onlyearly-responding tissues and that the parameters of thelinear quadratic model had large uncertainties. Forexample, in two of Urano et al.’s duplicate,single-fraction experiments, the / ratios differed bya factor of 2.5.Finally, the second study by Urano et al19 reported RBEvalues for weight loss in mouse testes, measured 35days after irradiation. The animals were irradiated with0.5 to 5 Gy, administered to their whole body. At thelevel of 20% weight loss relative to non-irradiatedcontrol animals, the RBE value was 1.21 ± 0.08. Thephoton dose at this effect level was 0.7 Gy. The weightloss dose dependence was best described by a linearfunction of the dose logarithm, and therefore the dataare outside the scope of the linear quadratic model.Overall, except this last example, our model wascompatible with prior experimental data. These data,however, are not sufficient to allow for confidentconfirmation or rejection of the model. Experimentaldata for a broader range of / ratios are needed forthat. It must be added that Paganetti et al.’s study5disputed the dosimetry of these earlier experiments.17-19Accordingly, the RBE values reported in these earlierstudies were adjusted accordingly resulting in lowervalues. This correction was justified by a reportaddressing a problem with a clinical dosimetry protocolat the Harvard Cyclotron Laboratory that was based onFaraday Cup methods for absolute dose calibration.21 Onthe other hand, the methodology described in theoriginal publications17-19 appears to be adequatebecause a calorimeter used for “an independent check ofthe dosimetry agreed with the standard dosimetry …within 0.8 to 2.6%”.22 For this reason, I have quotedunadjusted RBE values in this paper.I also applied my model to an analysis of the in vivo datasummarized by Paganetti et al.5 The median photondose per fraction for experiments in which the RBEvalue was measured in the middle of a spread-out Braggpeak was 12 Gy. The median RBE value was 1.1, and thestandard deviation of the RBE was 0.1. On the basis ofthese observations, I assumed that the RBE of 1.1 wasmeasured at 12 Gy per fraction. This assumptionidentified a single data point representative of a typicalfor this data set experiment that I chose to demonstratethe potential effects of fractionation on the RBE. I thenused this data point and my formalism to calculate theRBE value for a standard fractionation schedule of 37fractions with total doses of 5, 30, and 67.3 Gy. In thiscalculation, the number of fractions and the highest doserepresent a typical prescription for proton radiotherapy
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for prostate cancer23, and the lower doses are relevantfor normal tissue exposure. The calculated RBE valuesare shown in Figure 1 as functions of the  / ratio. Itshows that for early-responding tissues the RBE valuemay exceed 1.2. This is significantly higher than thepreviously reported RBE of 1.10  0.01.5 Figure 1 alsosuggests that the RBE value for late-responding tissuescan be even higher, especially at low doses. This latterobservation agrees qualitatively with data from thestudy by Gerweck and Kozin.7 However, the results forlate-responding tissues should be viewed with cautionbecause the assumed RBE value of 1.1 at 12 Gy wasderived from experimental data that was mostly forearly-responding tissues. Furthermore, the uncertaintiesof the data in Figure 1 are rather large. This isdemonstrated by the error bars shown for three datapoints on the 30-Gy curve. The confidence intervalswere calculated with the assumption that the confidenceinterval for the RBE value measured at 12 Gy perfraction was 1.0-1.2, and Eq. (2) was used for errorpropagation. It can be seen that the uncertainties in RBEvalue are much larger than the previously reported5standard deviation of 0.01 suggests.
4. ConclusionThe above results were derived using a method based onthe linear quadratic model and that was tested usingprior experimental data. The results suggest that there isa risk of significant deviations from the widely acceptedRBE value of 1.1. This study reports the estimatedmagnitude of such deviations. The results also indicatethat an RBE value of 1.1 is likely to be anunderestimation especially for late-responding tissuesreceiving low proton doses. Therefore, it is important forfuture studies to provide more RBE data for clinicallyrelevant fractionation regimens for a broad range oftissue types.
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